An update of recent moclobemide interaction data

  title={An update of recent moclobemide interaction data},
  author={Jasper Dingemanse},
  journal={International Clinical Psychopharmacology},
  • J. Dingemanse
  • Published 1 January 1993
  • Chemistry, Medicine
  • International Clinical Psychopharmacology
The classical monoamine oxidase inhibitors (MAOIs) are believed to have serious risks because of interactions with other drugs and foodstuffs, although not with a sound scientific basis in all cases. However, moclobemide, a selective reversible inhibitor of MAO-A, has a low propensity for producing drug interactions. Interaction studies have been carried out in healthy volunteers in an attempt toanswer some relevant practical questions related to therapy with moclobemide. In combination with… Expand
Moclobemide : An Update of its Pharmacological Properties and Therapeutic Use.
Comparative studies have established that moclobemide is better tolerated at therapeutic dosages and has less toxicity in overdose than TCAs and nonselective, irreversible MAO inhibitors, and is also effective in patients with a primary diagnosis of social phobia. Expand
Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
It is suggested that therapeutic doses of moclobemide up to 300 mg daily can be given 24 hours after the last dose of treatment with either amitriptyline or clomipramine without major risks. Expand
Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide
Moclobemide is an example of a reversible MAO-A inhibitor which has been extensively studied and whose pharmacokinetic, clinical pharmacological and toxicological profiles have been thoroughly defined, and has an excellent tolerability profile both within the therapeutic dose range and in overdose. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders
SummaryMoclobemide, a novel benzamide, is a reversible inhibitor of monoamine oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders.Expand
Serotonin toxicity caused by moclobemide too soon after paroxetine-selegiline.
  • M. Wu, J. Deng
  • Medicine
  • Journal of the Chinese Medical Association : JCMA
  • 2009
This case demonstrates that serotonin toxicity may occur even with small doses of paroxetine, selegiline and moclobemide in combination, and Physicians managing patients with depression must be aware of the potential for serotonin toxicity. Expand
Drug interactions with selegiline versus rasagiline
The main focus of the present work is to demonstrate possible drug interactions described in the literature when using rasagiline and selegiline, which could lead to limitation in efficacy or to potential harm to the patient through an unforeseen alteration of efficacy. Expand
Food and Drug Interactions with Monoamine Oxidase Inhibitors
The most feared interaction of MAOIs is the interaction with tyramine, a compound contained in a number of foods and beverages, which may lead to hypertensive crises and the so-called ‘cheese reaction’. Expand
A review of the reversible MAO‐A inhibitor moclobemide in geriatric patients
A comparison of the relevant literature shows that moclobemide has advantages over other, classic, antidepressants because of better tolerability, fewer side effects and interactions, shorter latency of effect, and lower toxicity. Expand
Death following acute poisoning by moclobemide.
It was concluded that the manner ofdeath was suicide and that the unique cause of death was massive ingestion of moclobemide, and the other xenobiotics were considered of little toxicological relevance. Expand